CoChat
Sign Up
Cited by 127Cannabis and Cannabinoid ResearchSubstance Abuse Treatment and OutcomesForensic Toxicology and Drug Analysis

The DOI matches its Crossref record; 85 of the 88 references it cites were found in a registry or an index.

The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms

Campeny, E., López-Pelayo, H., Nutt, D., Blithikioti, C., Oliveras, C., Nuño, L., Maldonado, R., Florez, G., Arias, F., Fernández-Artamendi, S., Villalbí, J.R., Sellarès, J., Ballbè, M., Rehm, J., Balcells-Olivero, M.M., Gual, A.·2020·European Neuropsychopharmacology
DOI 10.1016/j.euroneuro.2020.02.003
Open this paper in CoChat — free account

Abstract

Cannabis is the third most used psychoactive substance worldwide. The legal status of cannabis is changing in many Western countries, while we have very limited knowledge of the public health impact of cannabis-related harms. There is a need for a summary of the evidence of harms and risks attributed to cannabis use, in order to inform the definition of cannabis risky use. We have conducted a systematic review of systematic reviews, aiming to define cannabis-related harms. We included systematic reviews published until July 2018 from six different databases and following the PRISMA guidelines. To assess study quality we applied the AMSTAR 2 tool. A total of 44 systematic reviews, including 1,053 different studies, were eligible for inclusion. Harm was categorized in three dimensions: mental health, somatic harm and physical injury (including mortality). Evidence shows a clear association between cannabis use and psychosis, affective disorders, anxiety, sleep disorders, cognitive failures, respiratory adverse events, cancer, cardiovascular outcomes, and gastrointestinal disorders. Moreover, cannabis use is a risk factor for motor vehicle collision, suicidal behavior and partner and child violence. Cannabis use is a risk factor for several medical conditions and negative social consequences. There is still little data on the dose-dependency of these effects; evidence that is essential in order to define, from a public health perspective, what can be considered risky use of cannabis. This definition should be based on quantitative and qualitative criteria that informs and permits the evaluation of current approaches to a regulated cannabis market.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.euroneuro.2020.02.003

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 3

  1. Budney, 2019, 269, 73
  2. Crean, 2011, 5, 1
  3. Marconi, 2016, Meta-analysis of the association between the level of cannabis use and risk of psychosis, Schizophr. Bull., 42, 1262, 10.1093/schbul/sbw003 · DOI · Paper page

Cited by

Sorted by citations

See all 127

Related

See all

Metadata

Authors
Campeny, E., López-Pelayo, H., Nutt, D., Blithikioti, C., Oliveras, C., Nuño, L., Maldonado, R., Florez, G., Arias, F., Fernández-Artamendi, S., Villalbí, J. R., Sellarès, J., Ballbè, M., Rehm, J., Balcells-Olivero, M. M., & Gual, A.
Affiliations
  • Hospital Clínic de Barcelona (ES)
  • Imperial College London (GB)
  • Universitat Pompeu Fabra (ES)
  • Agencia de Salud Pública de Barcelona (ES)
  • Institut d'Investigació Biomédica de Bellvitge (ES)
  • Centre for Addiction and Mental Health (CA)
Corresponding author
Campeny, E.
ORCID
Venue
European Neuropsychopharmacology
Publisher
Elsevier BV
Published
2020-04
Volume
33
Pages
1-35
ISSN
0924-977X (ISSN-L)
DOI
10.1016/j.euroneuro.2020.02.003
OpenAlex
W3011169996
Cited by
127
References
88
Citations by year
2026: 6 · 2025: 20 · 2024: 11 · 2023: 26 · 2022: 33 · 2021: 22 · 2020: 9
FWCI
2.94
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • European Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Instituto de Salud Carlos III
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Keywords
cannabis use, cannabis-related harms, psychosis, mental health, personal injury, cardiovascular outcomes, respiratory adverse events, traffic accidents, suicidal behavior, violence, dose-response relationship, cannabis legalization
MeSH terms
Accidents, Systematic Reviews as Topic, Adolescent, Adult, Aged, Aged, 80 and over, Animals, Cannabis, Female, Humans, Male, Marijuana Smoking, Mental Health, Middle Aged, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review